Wilfred Ngwa is a distinguished scientist and global health leader whose career spans physics, oncology, Radiation Oncology and international cancer research. Studying initially in biophysics and physics at the University of Leipzig, where he earned both his MSc and PhD, he later specialized in radiation oncology through advanced training at leading institutions such as the MD Anderson Cancer Center and Harvard Medical School.

Over the years, he has built an impressive academic and clinical career, holding teaching and research positions across prestigious universities including Harvard University, Tufts University, and the University of Massachusetts Lowell. Currently, he serves as a professor of oncology and radiation oncology at Johns Hopkins Medicine, while also contributing at the highest policy and innovation levels as a program manager at the U.S. Advanced Research Projects Agency for Health.

Ngwa is widely recognized for his leadership in global oncology. He is the founding director of the Global Health Catalyst initiative, bridging institutions like Harvard and Johns Hopkins, and the founder of Global Oncology University, both aimed at reducing global cancer disparities. His influence extends to major international efforts, including leadership roles in commissions of The Lancet Oncology focused on cancer care in sub-Saharan Africa and the U.S. cancer workforce.

His research portfolio is extensive, with over 100 publications covering cutting-edge topics such as nanoparticle-enhanced radiotherapy, imaging technologies, and global health innovations in cancer treatment. His work bridges fundamental physics and clinical application, contributing significantly to advances in radiotherapy and cancer care accessibility worldwide.

Throughout his career, Ngwa has received numerous prestigious awards recognizing both scientific excellence and global impact, including the U.S. President's Lifetime Achievement Award and honors from leading professional bodies in medical physics and oncology. His career reflects a unique combination of scientific innovation, academic leadership, and a strong commitment to addressing global health inequities.

He was newly appointed program manager for the ARPA-H program 1 cure with a funding of few hundreds millions of dollars with the aim to develop a single, rapid, low-cost, and accessible radiotherapy approach to battle all types of cancer, including local, metastatic and RT-resistant cancers.